The Lancet (2021) This Phase 2 dose-finding trial randomized adults with overweight or obesity without diabetes to cagrilintide at doses from 0.3 to 4.5 mg weekly, placebo, or liraglutide 3.0 mg daily as an active comparator across 57 sites in 10 countries
Review the common peptide mistakes before beginning any advanced stack
In addition, centrilobular necrosis, cellular hypertrophy and vacuolization were observed (Figures 3C, D)
Patient information Leaflet Ingredients Active Ingredients: Semaglutide Other Ingredients: Disodium phosphate, dihydrate, Propylene glycol, Phenol, Hydrochloric acid (for pH adjustment), Sodium hydroxide (for pH adjustment) and Water for injection Product Information Brand Name: Wegovy Route of Administration: Subcutaneous Legal Classification: Prescription Only Medication (POM) Strength: 0.25mg, 0.5mg, 1mg, 1.7mg 2.4mg and 7.2mg Dosage Form: Solution for injection Storage Keep this medicine out of the sight and reach of children
presented at ADA 2026 (June 6, 2026)